Rupal S. Bhatt, MD, PhD, discusses the potential identification of a pathway of resistance for PD-L1 in renal cell carcinoma.
Rupal S. Bhatt, MD, PhD
Advertisement
Articles by Rupal S. Bhatt, MD, PhD
Rupal S. Bhatt, MD, PhD, discusses the discovery of HHLA2/KIR3DL3, a novel therapeutic immune checkpoint pathway in renal cell carcinoma.
Advertisement
Latest Updated Articles
Dr. Bhatt on Identification of Immune Checkpoint Pathway in RCCPublished: October 2nd 2019 | Updated:
Dr. Bhatt on Finding a PD-L1 Pathway of Resistance in RCCPublished: October 25th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5